Redirecting to https://investors.pfizer.com/investor-news/press-release-details/2019/FDA-Approves-Pfizers-Biosimilar-RUXIENCE-rituximab-pvvr-for-Certain-Cancers-and-Autoimmune-Conditions/default.aspx...

Click here if your browser doesn't automatically take you to this page.